anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To provide an antirheumatic agent containing a 2-acylthio-methyl-3- benzyolpropionic acid derivative as an active component, having weak side effect and toxicity and excellent immuno-regulation function and effective for the remedy of immuno-insufficiency diseases. CONSTITUTION:A benzoylpropionic acid derivative of formula I (R&lt;1&gt; is H, lower alkyl, etc.; R&lt;2&gt; is lower alkyl or phenyl; X is H, halogen, etc.; Y is H or lower alkyl) is used as an antirheumatic agent. The compound of formula I strongly suppresses adjuvant arthritis and has immuno-regulating activity and antiarthritis activity. The compound of formula I is useful also as a remedy for immuno- insufficiency diseases such as arthrorheumatism, autoimmune diseases, various carcinomas, bacteriosis, asthma, hepatopathy, etc., and has low side effect and toxicity. The compound can be produced by reacting the compound of formula II with the compound of formula R&lt;2&gt;COSH in an organic solvent in the presence of a basic catalyst.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a galenical powder-containing tablet having such strength as not to cause abrasion, nor breakage, when packaged and transported, small-sized, and containing a galenical powder in a high concentration.  &lt;P&gt;SOLUTION: This galenical powder-containing tablet is obtained by adding/mixing a powder into a galenical powder-containing granulated material into a powder, and then subjecting the mixture to compression molding (tableting), so that the tablet having a content of the galenical powder of ≥50 mass % based on a total amount of the tablet is obtained, wherein the galenical powder-containing granulated material is obtained by subjecting a mixed powder which contains the galenical powder and light anhydrous silicic acid having an average particle size of ≤0.05 μm in an amount of 0.001-0.2 pt.wt. based on 1 pt.wt. of the galenical powder to wet granulation and the powder contains light anhydrous silicic acid having an average particle size of ≥0.5 μm and a specific surface area of ≥100 m&lt;SP&gt;2&lt;/SP&gt;/g in an amount of 0.001-0.2 pt.wt. based on 1 pt.wt. of the galenical powder.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a hair dye composition capable of suppressing a sensitizing property.  &lt;P&gt;SOLUTION: This hair dye composition comprises (A) a direct dye and (B) a monoterpene-based hydrocarbon. The component B is preferably a cyclic monoterpene. The cyclic monoterpene is preferably at least one kind of compound selected from pinene, terpinene and limonene. The terpinene is preferably at least one kind of compound selected from α-terpinene and γ-terpinene. Both of the α-terpinene and the γ-terpinene are preferably contained in the hair dye composition.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE:A cosmetic, obtained by incorporating an aqueous cosmetic with gaseous carbon dioxide, and sealing up the resultant cosmetic in a pressure resistant container, and capable of exhibiting the vasodilator action in use and giving stimulus to the skin in use and further comfortable feeling of use. CONSTITUTION:A cosmetic obtained by incorporating gaseous carbon dioxide (preferably 60ppm or more) in a cosmetic with a relatively high moisture content, e.g. a toilet water, emulsion, hair lotion or shampoo, etc. adjusting the pH to 7 or below, particularly 5-6.5, and sealing up the resultant cosmetic in a pressure resistant container. The gaseous carbon dioxide is incorporated by putting the cosmetic in the pressure resistance container, and sealing up high- pressure gaseous carbon dioxide therein or putting a cosmetic containing a carbonate in the pressure resistant container, and adding a pH adjuster thereto to evolve and seal up gaseous carbon dioxide therein, etc. Preferably, the high- pressure gaseous carbon dioxide is sealed up therein. The pressure in the container is preferably kept at 1.2-8kg/cm&lt;2&gt; (gauge pressure) at 35 deg.C.
PURPOSE:To obtain a transparent gelatinous compsn. giving a good feeling after use, excellent in shelf stability, favorable to the skin and excellent also in cleaning effect by adding a mixture of polyglycerol fatty acid ester with a large amt. of liq. oily material to a mixture of polyol with water. CONSTITUTION:A mixture of polyglycerol fatty acid ester represented by the formula [where R1 is a 12-18C acyl, each of R2 and R3 is a 12-18C acyl or H and (n) is an integer of 0-8] with 40-90wt.% liq. oily material based on the amt. of the resulting compsn. is added to a mixture of water with &gt;=4 times as much polyol as the water. The amt. of the polyol is 5-59wt.% of the amt. of the resultant compsn. They are mixed to obtain the objective transparent gelatinous compsn. and this compsn. is used as a shampoo and face cleanser.
The invention relates to the technical field of artificial intelligence, in particular to an intelligent medicine taking management system and a medicine taking management method. The system comprises an intelligent medicine supply unit, a medicine taking detection and reminding unit and a remote end small program unit of a mobile phone of a caretaker. The intelligent medicine supply unit provides corresponding medicines according to preset time. The medicine taking detection and reminding unit monitors the medicine taking and taking process of a patient in real time by using a camera, and recognizes the medicine bag, the medicine taking action and the existence of a tablet in real time by a computer vision technology deep learning algorithm, so that the accuracy and the completion degree of medicine taking are judged in real time. Meanwhile, the system supports real-time video and voice interaction, and caregivers can remotely check the medication condition of patients. All real-time medication information is synchronized to the caretaker&#39;s mobile phone, providing a comprehensive remote caretaking experience. The system improves the convenience of medicine taking detection, improves the speed and accuracy of medicine taking detection, and is particularly suitable for old chronic patients needing remote care.
The present invention encompasses a receptor molecule present on the surface of natural killer cells (NK cells) and non-specific cytotoxic cells (NCC) which is involved in non-specific lysis of target cells bearing an antigen recognized by the receptor molecule, an antigen common to the surface of cells recognized and lysed by natural killer cells, monoclonal and heterologous antibodies which bind to the receptor and target cell antigen(s) which are useful in their identification and purification, and methods for altering NK cell-mediated lysis of target cells. The monoclonal antibodies (mAbs) of the present invention were prepared by cell fusions between spleen cells from mice immunized with either non-specific cytotoxic cells (NCC) from catfish (anti-receptor antibodies) or NC-37 human lymphoblastoid B-cells, which are susceptible to lysis by NK cells, and myeloma cells. Eight distinct mAbs have been characterized, four directed against the NK/NCC target cell receptor and four against the NK/NC cell antigen. As used in the present invention &#34;NK cells&#34; will be used to include both natural killer cells of mammalian origin and non-specific cytotoxic cells of fish origin, unless specifically stated otherwise. Two of the mAbs directed against the receptor and two of the mAbs against the NK target cell antigen are able to significantly inhibit NK lysis at low mAb concentrations, as assessed by inhibition of cellular toxicity. Two of the mAbs directed against the receptor and two of the mAbs against the NK target cell antigen bind to the antigen(s) but do not inhibit lysis.
A software system provides an interface between a radiology information system (16) and a central dictation system (14). The software includes first and second application modules which are both in communication with a database management system (12). Other components of the software system include protocole DLL&#39;s (dynamic linked libraries) (28) and a communication DLL (26). Each of the software components maintains a separate trace buffer. An event occurring in any one of the components triggers a dump of all of the trace buffers. A server socket object is maintained in existence and placed in an accept mode when a client socket terminates communication with the server socket object.
PURPOSE: To obtain the subject preparation composed of a phenylglycine derivative having a specific structure and its salt, and excellent in beautifying effect such as prevention of spots, freckles, pigmentation into skin after sunburn, etc., with melanin production-suppressing effect and having excellent stability and high safety. CONSTITUTION: This preparation is composed of a phenylglycine derivative of the formula (X1 and X2 are each H, OH or methoxy; m and n are each a natura1 number; m+n=&lt;=5; R1 , is carboxyl, alkoxycarbonyl, carbamoyl, etc.; R2 is H, an alkyl, benzoyl, etc.) and/or its salt. The compounding ratio of the compound is preferably 0.1-7wt.% based on the total weight of the preparation. Examples of the compound of the formula include L-p- hydroxyphenylglycine, 4-hydroxy-3-methoxy-D-phenylglycine, etc. Further, the external preparation is preferably formulated into a cream, an ointment, a gel, a lotion, etc.
PURPOSE:To provide a novel peptide having specific amino acid sequences isolated from the skin of Nigromaculata, etc., having a strong histamine- releasing activity and an antibacterial activity against gram-positive bacteria, gram-negative bacteria, etc., and useful as an antibacterial agent. CONSTITUTION:The skin of Nigromaculata, Rana.brevipoda, etc., is extracted with a 1M acetic acid solution under boiling, and they filtered. The filtrate is dialyzed through a dialytic membrane cutting molecules having mol.wts. of &gt;=1000 with a 1M acetic acid solution for 12hr to remove salts and low mol.wt. amines. The solution inside the dialytic membrane is passed through a gel filtration column and subsequently eluted with a pyridine-acetic acid solution. The eluted fraction is concentrated and dried under vacuum, dissolved in water, and subsequently subjected to a reverse phase high performance liquid chromatography, followed by separating an elusion fraction having an antibacterial activity to provide the objective peptide having amino acid sequences of formulas I and II, the brevinin-1 of formula I having an antibacterial activity against gram-positive bacteria, and the brevinin-2 of formula II having an antibacterial activity against gram-positive bacteria and gram-negative bacteria.
The invention relates to a traditional Chinese medicine formula for treating insomnia. With continuous rising of people&#39;s living standards, people&#39;s living pressure is increased continuously so that people usually have insomnia symptoms. The insomniac usually keeps awake overnight, thus having a poor spirit so that work efficiency is reduced in the next day and even the rest of other people can be influenced by the insomniac. Psychasthenia, memory deterioration, attention deficit and comprehension decline are caused by insomnia and thus body health can be influenced seriously. A use method of the traditional Chinese medicine formula for treating insomnia comprises that millet, lotus seeds, lily, arillus longan and Chinese dates are cleaned by clean water, are put into a pot together, are mixed with clean water and are boiled by a slow fire for 40 minutes to form congee. Through frequent use, the traditional Chinese medicine formula for treating insomnia has the body-building effects of soothing the nerves and helping sleep, tonifying qi, nourishing blood, and strengthening the heart. The traditional Chinese medicine formula for treating insomnia is especially suitable for old people.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a hypoglycemic agent containing a polysaccharide sulfate, especially, a heparin or a heparan sulfate, as an active ingredient, highly safe, and extremely clinically effective.  &lt;P&gt;SOLUTION: This hypoglycemic agent contains the polysaccharide sulfate as the active ingredient. The hypoglycemic agent preferably contains a glycosaminoglycan having a sulfate group as the active ingredient. The hypoglycemic agent especially preferably contains the heparin or the heparan sulfate as the active ingredient. Each of compounds called &#34;heparin&#34; and &#34;heparan sulfate&#34; in the specification may comprise a low-molecular saccharide chain in which a disaccharide unit thereof is contained, as well as the polysaccharide, or comprise a pharmaceutically acceptable salt thereof.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
In some embodiments, the present disclosure provides methods for stimulating a subject&#39;s immune system. Particular methods provide a tumor specific immune response by injecting a tumor with a magnetorheological fluid and applying a magnetic field to the tumor. The immune response can be used to treat disseminated tumors or metastatic cells. Further methods induce a general immune response, such as by treating a section of tissue, such as healthy tissue, with a magnetorheological fluid and applying a magnetic field to the treated tissue. The immune response can be used to treat illness or disease or to enhance the effect of a therapeutic agent. In particular examples, the disclosed methods are used to enhance the effect of immuno stimulants. Also provided are methods for causing necrosis of a cell mass, such as a tumor, by injecting a magnetorheological fluid into a section of tissue and applying a magnetic field to the tissue.
PURPOSE: To obtain a microcapsule having a given size, consisting of acetylsalicylic acid(ASA) coated with a coating composition, and capable of controlling ASA release over the whole length of the digestive tract. CONSTITUTION: This microcapsule consists of an ASA particle 10-100 μm in size coated with a coating composition of a mixture of a cellulose-based film- forming polymer derivative, anti-tack agent, plasticizer, lubricant and vinyl-based film-forming polymer derivative. In the case of a single oral administration of the microcapsules at 75-320 mg, ASA absorption is induced over 24 h or longer. ASA absorption levels based on the portion to be absorbed are as follows: &lt;=10 wt.% at 0.4 h after orally administered, &lt;=50 wt.% at 3.9 h after orally administered, and &lt;=90 wt.% at 23 h after orally administered. The microcapsules, for inhibiting thromboxane, can be used for preparing a selective aspirin galenical preparation, esp. being applicable, as a platelet aggregation inhibitor, against cardiovascular diseases.
PURPOSE:To provide an MRI opaque substance which has a sufficient opaque capacity in a physiologically permitted opaque substance concn. region and with which useful image information is obtainable by using a polyamine metal complex compd. formed by coordinate bond of a polyamine ligand having &lt;19&gt;F to paramagnetic metal ions as a compd. having opaque activity. CONSTITUTION:This opaque substance consists of the polyamine metal complex compd. formed by coordinate bond of the polyamine ligand having &gt;=1 fluorine atoms to the paramagnetic metal ions. The paramagnetic metal is selected from a group consisting of chromium, manganese, iron, copper and gadolinium. The NMR chemical shifts of the plural fluorine atoms are all substantially the same and are all distributed within the region of &lt;=2000Hz width. On the other hand, a tissue specific material having specific affinity to the specific biotissue to be opacified is bonded via an adequante linker to the polyamine ligand. The tissue specific material is peptide and/or material contg. saccharides, monoclonal antibody.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a safe frequent urination-ameliorating composition, and a blood flow-ameliorating composition.  &lt;P&gt;SOLUTION: The frequent urination-ameliorating composition contains an essence of basidiomycetes, extracted from the mycelium-cultured product or the carpophore of the basidiomycetes. One kind selected from the group consisting of fungi of family Hydnaceae and Flammulina velutipes (Fr.) Sing. is used as the basidiomycetes. The essence is obtained by extracting the carpophore/mycelium of the basidiomycetes with hot water at 50-80°C or ethanol at 40-60°C, and subjecting the extract to lactobacillus fermentation.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
ABSTRACT OF THE DISCLOSURE:           N-lower alkyl neoalkanamides (N-lower alkyl trialkyl-acetamides of certain types) of 1 to 4 carbon atoms in the lower alkyl thereof  and of 5 to 14 carbon atoms in the neoalkanoyl (or trialkylacetyl) group, e.g., N-methyl- and N-ethyl neodecan-amides and N-methyl and N-ethyl neotridecanamides, are new compounds, secondary amides  which have insect repellent properties, being especially effective against cockroaches, e.g., the German cockroach.  However, they are also useful as repellents for other insects, including American cockroaches, mosquitoes, flies, fleas, ants, and lice.  Additionally, they may repel arachnids, such as spiders, ticks and mites.  The new neoalkanamides may be synthesized easily, as by reacting a primary lower alkyl amine with a neoalkanoyl halide, e.g. by reacting methyl amine or ethyl amine with neodecanoyl chloride.         The most effective of the described amides for insect repellency are normally liquid and are sufficiently volatile to be detectable in air by insects.  They may be applied directly to surfaces to be treated or they may be incorporated in detergent compositions, such as built laundry deter-gents, floor and wall cleaners, rug cleaners and shampoos, hair shampoos, and liquid and bar soaps, and have been found to be sufficiently substantive to the substrate being washed so as to impart insect repelling properties to it.  They may be dissolved, dispersed or emulsified (emulsions are considered to be special cases of dispersions) in appropriate liquid media and may be applied to surfaces to be made insect repellent, as by spraying, brushing, wiping or other suitable processes, includ-ing &#34;aerosol&#34; spraying from pressurized containers.  They have been found to be of long lasting effectiveness, with significant and measurable insect repellency being obtainable for as long as two weeks after application.  The described N-lower alkyl neoalkanamides are stable during normal uses, relatively low in manufacturing cost, of high substantivities to substrates, economical to use, unobjectionable in odor to humans, and harmless to humans and animals, and to the environment.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a skin ageing-preventing agent and/or pimple-improving agent kit which comprise external and internal preparations exhibiting a skin ageing- preventing action and a pimple-improving action, when used together simultaneously or within a prescribed time, and utilizes the anti-oxidizing ingredient, to provide a skin ageing-preventing and/or pimple-improving beauty method which utilizes together both percutaneous application and oral application, and to provide a pimple-improving food composition.  &lt;P&gt;SOLUTION: This skin ageing-preventing agent and/or pimple-improving agent kit comprises the external preparation containing an anti-oxidizing ingredient and the internal preparation containing an anti-oxidizing ingredient. The internal preparation further contains a wound-curing ingredient and a blood circulation-stimulating ingredient. The anti-oxidizing ingredient includes parsley, tea, yeast and wheat embryo bud. The wound-curing ingredient includes Centella asiatica, Euonymus trichocarpus HAYATA, Panax ginseng, and collagen peptide. In the skin ageing-preventing and/or pimple-improving beauty method, an anti-oxidizing ingredient is percutaneously applied, and the other anti-oxidizing ingredient is orally administered. The pimple-improving food composition comprises carotene, vitamin C, tocotrienol, a Centella asiatica extract, and the like.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a formulation for treatment of asthma, free of CFC (chlorofluorocarbon), having desirable solubility, stability, low toxicity, accurate dosage, correct particle diameter and/or compatibility with conventionally used valve assembly of inhalator for measured dosage and to provide a method for producing the formulation.  &lt;P&gt;SOLUTION: Disclosed are aerosolized formulations for the treatment of asthma (that contain mometasone furoate and formoterol fumarate) and methods for preparing the same. Accordingly, the present invention is directed to a process for producing non-toxic formulations that are substantially free of CFC&#39;s that have improved stability and compatibility with the medicament and which are relatively easily manufactured. The formulations are produced according to conventional procedure in the technological field in respect to other aerosol composition. Typically, all components other than the propellant are mixed and introduced into an aerosol container.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has room temperature stability advantages over known forms and dichloride salts. The novel crystalline form is characterized by having peaks at 22.9, 25.4, 25.8, 26 in the XRPD spectrum.6. Peaks and Raman shifts 943, 1173, 1527 and 1612 + -5 cm at 34.6 and 35.3 + -0.1 deg. 2 theta ‑1 . Crystalline forms of triethylenetetramine tetrachloride are useful for treating Wilson&#39;s disease. Also disclosed is a process for preparing a crystalline form of triethylenetetramine tetrachloride comprising adding an antisolvent to an aqueous solution of the compound.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a comparatively inexpensively produceable and highly safe hair cosmetic composition, having not only excellent hydrogen peroxide-removing effects but also repair-promoting effects of damaged hair, and to provide a method for producing the hair cosmetic composition.  &lt;P&gt;SOLUTION: The hair cosmetic composition contains a fermented product obtained by fermenting a raw material containing at least one kind selected from a fruit, a vegetable and a juice thereof by catalase-positive microorganisms as an active ingredient. The cosmetic composition for the hair can be obtained by adding the catalase-positive microorganisms to a pulverized product obtained by pulverizing the fruit or the vegetable, or the juice thereof, and fermenting the resultant mixture. Preferably, Bacillus coagulans is used as the catalase-positive microorganisms. At least one kind of an orange, a peach, a mango and an apple is preferably used as the fruit, and at least one kind selected from a pumpkin, a potato, Brassica rapa, spinach and broccoli is preferably used as the vegetable.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a lubricant composition which is used for tablets, exhibits good tabletting moldability, and can give the tablets having high tablet hardness and good collapsibility.  &lt;P&gt;SOLUTION: This lubricant composition used for the tablets, comprising sucrose fatty acid esters and a 16 to 22C fatty acid salt, is characterized in that the sucrose fatty acid esters comprises 20 to 50 wt. % of a sucrose fatty acid ester having an esterification degree of 1 to 3, 30 to 60 wt. % of a sucrose fatty acid ester having an esterification degree of 4 to 6, and ≤20 wt. % of a sucrose fatty acid ester having an esterification degree of 7 to 8.  &lt;P&gt;COPYRIGHT: (C)2004,JPO